Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Current Deferred Revenue (2018 - 2025)

Ligand Pharmaceuticals' Current Deferred Revenue history spans 14 years, with the latest figure at $111000.0 for Q2 2025.

  • For Q2 2025, Current Deferred Revenue fell 90.72% year-over-year to $111000.0; the TTM value through Jun 2025 reached $111000.0, down 90.72%, while the annual FY2024 figure was $1.3 million, 4.58% up from the prior year.
  • Current Deferred Revenue for Q2 2025 was $111000.0 at Ligand Pharmaceuticals, up from $101000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $25.1 million in Q1 2021 and bottomed at $101000.0 in Q1 2025.
  • The 5-year median for Current Deferred Revenue is $1.2 million (2023), against an average of $5.8 million.
  • The largest YoY upside for Current Deferred Revenue was 476.64% in 2021 against a maximum downside of 97.78% in 2021.
  • A 5-year view of Current Deferred Revenue shows it stood at $654000.0 in 2021, then crashed by 45.72% to $355000.0 in 2022, then soared by 244.23% to $1.2 million in 2023, then increased by 4.58% to $1.3 million in 2024, then plummeted by 91.31% to $111000.0 in 2025.
  • Per Business Quant, the three most recent readings for LGND's Current Deferred Revenue are $111000.0 (Q2 2025), $101000.0 (Q1 2025), and $1.3 million (Q4 2024).